Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Research & Development: ¥194 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600329 Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
65 GF Score
Price ¥36.43
GF Value ¥23.63
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Research & Development?

Tianjin Pharmaceutical Da Ren Tang Group SHSE:600329 -1.49% 65 Research & Development is ¥194 Mil as of Mar. 2026. GuruFocus rates SHSE:600329 with a GF Score™ of 65/100 and a GF Value™ of ¥23.63 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tianjin Pharmaceutical Da Ren Tang Group's Research & Development for the three months ended in Mar. 2026 was ¥30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥194 Mil.

Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tianjin Pharmaceutical Da Ren Tang Group Research & Development Related Terms

Tianjin Pharmaceutical Da Ren Tang Group Research & Development Historical Data

* Premium members only.

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group Research & Development Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.05 153.15 184.63 162.38 189.81

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.78 35.77 43.07 85.19 29.81
SHSE:600329
65GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin Pharmaceutical Da Ren Tang Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥194 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥194 Mil mean?
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) has a Research & Development of ¥194 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors.
Is Tianjin Pharmaceutical Da Ren Tang Group's Research & Development too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Research & Development is ¥194 Mil. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Research & Development compare to ZTS?
Tianjin Pharmaceutical Da Ren Tang Group's Research & Development of ¥194 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current Research & Development is ¥194 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥23.63, compared to a current price of ¥36.43 — trading 54.2% above its estimated fair value. The current Research & Development is ¥194 Mil. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329), the current Research & Development is ¥194 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of ¥36.43 is trading 54.2% above its estimated GF Value™ of ¥23.63. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for SHSE:600329:

  • Research & Development: ¥194 Mil
  • GF Value™: ¥23.63 vs. price of ¥36.43 (54.2% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore2TZ:Germany
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
65GF Score

Get the complete analysis for SHSE:600329

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.43
Price
¥23.63
GF Value